JCI early table of contents for June 25, 2012

Public release date: 25-Jun-2012 [ | E-mail | Share ]

Contact: Sarah Jackson press_releases@the-jci.org Journal of Clinical Investigation

METABOLISM The skinny on what makes us fat

Obesity is a disorder in which fat cells grow larger and accumulate. Certain proteins, called WNT family proteins, function to prevent fat cell formation. However, the activity of WNT proteins can be inhibited by secreted frizzled-related proteins (SFRPs), thus leading to fat cell generation. One of these SFRPs, SFRP5, is highly expressed during fat cell generation and increases during obesity. Dr. Ormond MacDougald and colleagues at the University of Michigan sought to determine the mechanism of SFRP5-mediated obesity and found that mice lacking SFRP5 were resistant to diet-induced obesity, despite having similar numbers of fat cells as control mice. The results from a transplantation experiment wherein fat tissue was transferred from SFRP5-deficient mice into obesity-prone mice demonstrated that the mechanism of SFRP5-mediated inhibition of fat cell generation is specific to the tissue itself and not dependent on the surrounding environment. The team also found that SFRP5-deficient mice showed increased metabolic activity compared to control mice. These findings, which were discussed in a commentary by Alexander Rauch and Susanne Mandrup at the University of Southern Denmark, shed light on the mechanism of SFRP5-mediated obesity and identify the WNT signaling pathway as a potential therapeutic target to counteract obesity.

TITLE:

Regulation of adipocyte mitochondrial biogenesis and metabolism by secreted frizzled-related protein 5 and WNT signaling

AUTHOR CONTACT:

Ormond MacDougald University of Michigan, Ann Arbor, MI, USA Phone: (734) 647-7721; Fax: 734 232-8175; E-mail: macdouga@umich.edu

ACCOMPANYING COMMENTARY

TITLE:

More here:
JCI early table of contents for June 25, 2012

Healthscope to commercially launch Circadian's Cancers of Unknown Primary Diagnostic Test

MELBOURNE, Australia, June 26, 2012 /PRNewswire/ --Circadian Technologies Limited (ASX: CIR, OTCQX: CKDXY) announces that it has been advised by its development partner, Healthscope Advanced Pathology, that it will commercially launch Circadian's novel technology for aid in the diagnosis of "Cancers of Unknown Primary" (CUP), on Monday July 16 2012 in Australia, New Zealand, Singapore and Malaysia under the brand CUPGUIDE.

The diagnostic test method has been developed in collaboration between Circadian, Healthscope, the Peter MacCallum Cancer Centre, a leading specialty cancer centre, and scientists at NICTA, Australia's Information and Communications Technology (ICT) Research Centre of Excellence.

A publication in March 2012 from Healthscope reported that the CUP test was able to detect actual primary source of tumour type with 93% accuracy within the first three predictions and had 98.5% specificity across 15 different tumour types.

Healthscope, through its subsidiary Clinical Laboratories Pty Ltd, has rights to develop, clinically validate and market the test throughout Australia, New Zealand, Malaysia and Singapore. Circadian retains rights to market the test in the remainder of the world. Healthscope has paid Circadian an upfront fee, and will pay a royalty on sales of the test. Circadian, through its wholly owned subsidiary Cancer Therapeutics Limited, owns exclusive worldwide rights to the test through a licensing arrangement with the Peter MacCallum Cancer Centre and NICTA.

The CUP diagnostic methodology identifies a patient's tumour type by comparing its pattern of gene expression to a database of known tumours. It is hoped that by correctly identifying a patient's tumour type, clinicians can choose the most effective treatment strategy for the cancer. CUP is generally less well known and publicised than other cancer types. However, it is actually more common than leukaemia and is the fifth most common cause of death due to cancer in Australia. In 2007, Cancer Council Australia estimated the incidence of CUP to be around 2900 case per annum; American Cancer Society estimated USA incidence at around 32,000 per annum and Cancer Research UK estimated UK incidence at 14,000 per annum.

Robert Klupacs, Circadian Managing Director and CEO stated, "We are absolutely delighted that after all of the efforts of the collaborative partners that CUPGUIDE will now be available to oncologists and pathologists. We are extremely hopeful that CUPGUIDE will have a major impact in significantly improving the clinical diagnosis of CUP."

Dr Keith Byron, Scientific Director of Healthscope's Advanced Pathology Division said, "Healthscope is proud and excited that after the extensive development program we have undertaken with our partners that we will now be able to provide this ground breaking diagnostic technology on a commercial basis. The test is an important addition to our existing business of providing diagnostic tools for doctors throughout our 43 hospitals and the health care industry in general."

Prof David Bowtell, Head of the Cancer Genomics Program at the Peter MacCallum Cancer Centre and a co-inventor of the diagnostic methodology added, "The approach was initially developed in our lab several years ago but the assay needed to be made more generally available. Circadian and Healthscope have been critical to taking the work forward and it is very gratifying that this product of our translational research efforts will be made available to clinicians throughout the region. The concept of personalising treatments for patients based on highly specialised diagnostics is now very well accepted in oncology and has been shown to have significant patient benefit. We believe that the assay will lead to earlier diagnosis, improved treatment outcomes and enhanced quality of life for patients."

Dr Adam Kowalczyk, Leader of Diagnostic Genomics Team in NICTA's Victorian Research Laboratory, and a co-inventor of the diagnostic methodology added, "It is very satisfying that formal techniques for signal detection and pattern recognition can be utilised in practical medical applications. This diagnostic test heralds imminent arrival of many new developments bringing promises of personalised medicine and genomics, in particular, to everyday usage that benefits patients."

Company enquiries

Read more:
Healthscope to commercially launch Circadian's Cancers of Unknown Primary Diagnostic Test

CepMed Appoints New CEO

MONTREAL, QUEBEC--(Marketwire -06/18/12)- Mr. Michel Saucier, Chairman of the Board of Directors of CepMed, the Center of Excellence in Personalized Medicine, is pleased to announce the appointment of Ms. Manon Decelles, CPA, CGA as Chief Executive Officer. Coincident with Ms. Decelles' arrival, Dr. Clarissa Desjardins, outgoing CEO, is leaving to manage a start-up biotechnology company.

Ms. Decelles has 20 years of experience in the pharmaceutical industry and a proven track record in key areas of business including finance, marketing and business development. Together with this experience Ms. Decelles brings an extensive business network that will enable CepMed in bringing together medical, scientific and business communities to promote innovation and commercialization in personalized medicine. Prior to joining CepMed, Ms. Decelles was Director of Business Development and Acquisitions at Sanofi, a global and diversified healthcare leader, where she was responsible for the Canadian affiliate's business development activities, including in and out licensing, divestitures as well as company acquisitions. In this capacity, Ms. Decelles developed and implemented a Strategic Business Development Plan and review process that guided Sanofi's Canadian strategy. Previously, Ms. Decelles held roles of increasing responsibility in finance, marketing and business development at Marion Merrell Dow, Hoechst Marion Roussel and Aventis. Ms. Decelles is an active member of the Board of Directors of the Canadian Healthcare Licensing Association.

Ms. Decelles first studied in science - microbiology at the University of Sherbrooke. She later obtained a Bachelor of Business Administration from the University of Montreal, HEC and is also a Chartered Professional Accountant (CPA).

"As Cepmed approaches its fifth year of operations, we believe that Manon's background and experience is perfectly suited to take Cepmed to the next level. Going forward, we expect to increasingly attract foreign investment in our centre for translational studies, commercialize the results of our studies and implement personalized medicine tests and strategies into our healthcare system. We welcome Manon to her new position and are confident that she can take on this challenge." - Mr. Michael Saucier, Chairman of the Board, CepMed

The Board extends its best wishes to Clarissa in her new endeavors and its deep gratitude for her contributions to CepMed and the advancement of personalized medicine in Canada. "Her leadership of our public-private partnerships and innovative knowledge translation activities including a Personalized Medicine Portal and the creation of physician's expert panels in cardiology, oncology and family medicine have created an awareness of personalized medicine and its benefits across the country." - Dr. Jean Claude Tardif, Director Montreal Heart Institute Research Centre

About CepMed

Founded by the Montreal Heart Institute and Genome Quebec in 2008, CepMed is a non-profit organization dedicated to promoting the science and practice of personalized medicine. It is a Centre of Excellence for Commercialization and Research (CECR) funded by the Canadian Government, Genome Quebec and industry partners including Pfizer, AstraZeneca, Novartis and Merck. Cepmed's initiatives are designed to promote and enable personalized medical treatment, based on the use of molecular information in clinical decision making, in particular to improve the efficacy and safety of drug therapy. Cepmed participates in several multi-million dollar public-private partnerships (PPP) in translational medicine that incorporate pharmacogenomics into Phase III clinical trials or studies of marketed drugs with partners including Roche and Servier. These partnerships leverage the expertise and capacities of The Beaulieu Saucier Pharmacogenics (PGx) Centre, The Montreal Heart Institute Coordinating Centre (MHICC) and The Montreal Heart Institute Biobank. Generating several millions of dollars in investment these partnerships have established a unique and world class centre for translational clinical research. In addition CepMed is collaborating and partnering with Canadian stakeholders in personalized medicine including physicians, patients, governments, industry and investors to enable the clinical development and implementation of personalized medicine while creating commercial opportunities for Canadian companies.

Here is the original post:
CepMed Appoints New CEO

Gentris Corporation Partners with the Shanghai Institutes of Preventative Medicine

MORRISVILLE, N.C., June 21, 2012 /PRNewswire/ -- Gentris Corporation (www.gentris.com), a global leader in the application of genomic biomarkers to clinical studies, announced today that it has signed a Memorandum of Understanding with the Shanghai Institutes of Preventative Medicine to advance global personalized medicine. The goal of this USA-China collaboration is to create translational research and epidemiological projects, as well as training and education programs, focused on pharmacogenomics and clinical sample banking, which will drive innovation in drug development and improvements in patient care.

Through this collaboration, Gentris and the Shanghai Institutes of Preventative Medicine will work together to launch cutting-edge research projects to discover, develop, and validate new genomic biomarkers. Gentris will take the lead to identify sponsors in the United States, e.g., pharmaceutical companies, for these personalized medicine projects while the Shanghai Institutes of Preventative Medicine will seek support from Chinese organizations.

The tuberculosis drug-induced liver injury pilot (TB DILI Study), conducted between Gentris, the Shanghai Institutes of Preventative Medicine, and a non-profit research institute in Research Triangle Park (RTP) serves as a model for USA-China collaborations. In this study, investigators designed a common protocol and pooled their resources to investigate DILI among tuberculosis patients in three Shanghai hospitals. By utilizing metabolomics and pharmacogenomics, they are evaluating biomarkers for early detection. Dr. Tong Zhou, Senior Director of China Initiatives for Gentris, is Co-Principal Investigator for the TB DILI Study and has significant experience in developing and managing collaborations between the United States and China. Dr. Zhou has also drawn upon his extensive network in China to begin establishing a satellite laboratory for Gentris in Shanghai that complies with U.S. regulatory standards.

Dr. Wu Fan, Director General of the Shanghai Institutes of Preventative Medicine and the Shanghai Municipal Center for Disease Control and Prevention (Shanghai CDC), and Dr. Howard McLeod from the University of North Carolina will provide strategic scientific oversight for personalized medicine collaborations. Director Wu is recognized internationally as a leader in public health initiatives. Dr. McLeod, Chief Scientific Advisor for Gentris, has been involved in numerous global initiatives including the Pharmacogenetics for Every Nation Initiative (PGENI), which he founded. It is anticipated that combining the resources and expertise of a research institute, academic institution, and industryin both the United States and Chinawill lead to more rapid improvements in drug development and public health.

For this personalized medicine program, research studies and epidemiological projects will be designed for implementation in Shanghai based on sponsor needs. Key targeted therapeutic areas include oncology, infectious disease, and chronic disease. Training and education initiatives will also be created to bring U.S. quality standards to China including GLP, GCP, CLIA, and CAP. Gentris, the Shanghai Institutes of Preventative Medicine, and their collaborators will work with leading experts to develop workshops, courses, and a fellowship program to educate academic and industry scientists in China regarding best practices in the application of pharmacogenomics for drug development.

The Memorandum of Understanding leverages the relationships that Gentris CEO Rick Williams and Dr. Zhou have built during the past few years between North Carolina and China. While assisting a non-profit research institute in RTP, they helped to create the North Carolina-China Global Bioscience Gateway, a public-private partnership that addresses how to enhance global research innovation. Mr. Williams and Dr. Zhou are also members of the N.C. China Advisory Council, which works with the N.C. Office of the Governor and N.C. Department of Commerce to facilitate economic development between the state and China.

One of the major goals for this new agreement between Gentris and the Shanghai Institutes of Preventative Medicine is to create an expanded network of collaborators among leading universities, pharmaceutical companies, and public health organizations that leads to new pharmacogenomics discoveries, which accelerate drug development and improve patient care globally.

Related Links: http://www.gentris.com, http://www.scdc.sh.cn

Quotes:

"I have worked with the Shanghai CDC and Shanghai Institutes of Preventative Medicine for nearly four years to develop a translational research bridge between our two countries. I'm honored that Gentris now has an opportunity to work even more closely with the Shanghai Institutes of Preventative Medicine," said Rick Williams, Gentris CEO. "Gentris will take the lead to identify U.S. sponsors in the pharmaceutical industry that would like to jointly develop new research, epidemiological, and training programs in Shanghai."

Follow this link:
Gentris Corporation Partners with the Shanghai Institutes of Preventative Medicine

Frost & Sullivan: Expanding Sample Prep Market Supports Growth Trends in Molecular Diagnostics Markets

Biomarker validation analyses create surge in demand for formalin-fixed, paraffin-embedded sample prep solutions

MOUNTAIN VIEW, Calif., June 21, 2012 /PRNewswire-Asia/ -- Hundreds of millions of formalin-fixed, paraffin-embedded (FFPE) archive specimens available globally have piqued tremendous interest for biomarker validation studies, generating a surge in demand for FFPE sample prep solutions. FFPE archive specimens from patients with known clinical outcomes provide an economic and readily available source for the biomarker validation needed to develop clinical molecular cancer tests.

Analysis from Frost & Sullivan's (http://www.clinicaldiagnostics.frost.com( http://www.frost.com/prod/servlet/svcg.pag/HCCD )) Demand Analysis of U.S. Cancer Sample Prep Market research finds that automated sample prep systems developed specifically for FFPE provide greater sample throughput and satisfy the requirements of various end users.

If you are interested in more information on this research, please send an email to Britni Myers, Corporate Communications, at britni.myers@frost.com( mailto:britni.myers@frost.com ), with your full name, company name, job title, telephone number, company email address, company website, city, state and country.

Archived tissues are Institutional Review Board (IRB) exempt and are a feasible alternative to validating biomarkers when compared to costly prospective clinical trials. Therefore, pharmaceutical companies and research institutes are employing FFPE services for their pharmacogenomics programs.

"Translational research using FFPE archive specimens is helping to produce an expanding menu of future molecular-based cancer testing," said Frost & Sullivan Industry Analyst Winny Tan. "A Frost & Sullivan survey of molecular pathology labs in the United States reveals that nucleic acid extraction from FFPE specimens is poised for more than 20 percent volume growth in the next three years."

Molecular sample prep vendors have offered kits for FFPE specimens for the last three to five years. Process automation signals the brink of a market expansion fueled by the increased throughput. Additionally, clinical molecular tests for serine/threonine-protein kinase B-Raf (BRAF) and GTPase Kras (KRAS) gene biomarkers, as well as for epidermal growth factor receptor (EGFR), are driving the demand for the FFPE sample preps.

Sample prep for FFPE specimens that produce nucleic acid extractions of high purity and yield will become even more critical for downstream molecular testing. The clinical labs surveyed by Frost & Sullivan anticipate an inevitable integration of molecular extraction techniques with the long FFPE legacy that exists in solid tumor diagnostics.

However, growth of this market is hindered by the limited number of sites where molecular pathology is performed as well as the slow adoption of FFPE sample prep automation by hospital laboratories. Further, hospital budgets are restricted, and investments for FFPE sample prep automation compete with other top priorities, such as the implementation of electronic medical records. Despite these factors, the hospital segment is far from saturation, as it has long-term potential.

The FFPE sample prep automation market targets a variety of end user segments with different needs, applications, and perceptions; therefore, a strong understanding of relevant product specifications is critical for capitalizing on the market opportunity. Vendors must remain attentive to genomic analysis trends and emerging applications to keep pace with changing customer needs in specimen types, protocol customization and throughput.

See the rest here:
Frost & Sullivan: Expanding Sample Prep Market Supports Growth Trends in Molecular Diagnostics Markets

CareCapital Grp plc – Agreement with Varigen Technologies

12 June 2012

CARECAPITAL GROUP PLC

("CareCapital" or "the Company")

Agreement with Varigen Technologies

Diagnosis and Treatment of Malignant Diseases Based on Genetic Testing, Initially Targeted at Women's Health Care

CareCapital (AIM: CARE) announces that it has signed a mutually exclusive agreement ("the Agreement") with Varigen Technologies ("Varigen") to use Varigen's expertise in the areas of genetic testing and its application to both the diagnosis and development of personalized medical treatments for patients with malignant diseases. Under the Agreement, the specialist services supplied by Varigen will initially be made available at CareCapital's planned medical centre in Folkestone (Berlin: FKO.BE - news) , dedicated exclusively to women's health. Varigen will be entitled to a share, after deduction of all operating costs, of 30% of revenues derived from the provision of the services, with CareCapital retaining the remainder.

Varigen is a company established by Mark Hoser, an expert in the field of genetic and medical diagnostics. Following the award of a PhD from St Thomas' Hospital in haematology and coagulation diagnostics, Mark subsequently held various management positions with large, international pharmaceutical companies before founding GeneForm Technologies in 2003 to exploit his patents in molecular diagnostics and pharmacogenomics. After a successful trade sale of GeneForm Technologies, he has continued his focus on personalized medicine and rapid, next generation diagnostics as well as genotyping technologies for the prediction of drug efficiency in oncology.

Commenting on the Agreement, Mike Sinclair, CareCapital's CEO, said,"The addition of Mark's expertise via this agreement with Varigen Technologies is exactly on strategy for us as we build and grow our specialist cancer services business. The services developed with Varigen will be first available at our dedicated women's health care facility but can then be rolled out more widely."

Mark Hoser of Varigen, added, "The personalisation of diagnosis and treatment are critical steps in the future of medical care and translate to best care and improved quality of life for the patient. Varigen is excited to contribute to CareCapital's endeavour's in making this a reality."

For further information, please visit http://www.carecapital.co.uk or contact:

View original post here:
CareCapital Grp plc - Agreement with Varigen Technologies

AMP Receives 40% Increase in Abstract Submissions

Newswise Bethesda, MD, June 13, 2012: the Association for Molecular Pathology (AMP) announced a record-breaking number of abstract submissions for the AMP 2012 Annual Meeting on Genomic Medicine, marking a 40% increase over last year. The Meeting will be held October 25-27, 2012 in Long Beach, CA. An increase in the number of meeting attendees and exhibitors is anticipated as well. "The record growth in every phase demonstrates clearly how well-recognized it is that AMP offers the meeting of the year in molecular diagnostics and genomics," stated Iris Schrijver, MD, AMP President.

Growth in recent years and the spike in this years AMP Annual Meeting participation mirror the marked growth in the field of molecular pathology. AMP has had consistent growth in the number of abstracts submitted and number of attendees at the annual meeting, but the increase this year blew the lid off even our expectations, noted Mary Steele Williams, Executive Director, The AMP 2012 Annual Meeting on Genomic Medicine promises to be jam-packed with attendees and exciting scientific exchange.

As the only organization dedicated solely to the practice and science of molecular pathology, it is natural that the AMP Annual Meeting serves as the showcase for translational research, clinical practice, and practical technical discussions in all aspects of molecular diagnostics and genomic medicine. Abstract topics submitted for this years meeting span the breadth of molecular diagnostics, including the use of next generation sequencing in a clinical setting; novel tools for the detection of infectious agents; development and validation of new molecular tests; detection and analysis of various biomarkers in cancer.

Session topics chosen for this years meeting include; integrating pharmacogenomics into health care, utility of next generation sequencing, new molecular pathology CPT codes, and many more. AMP expects a record number of poster presentations at this years AMP Annual Meeting. With 400+ posters plus more than 30 hours of educational sessions and 55 presentations, this years event is expected to be the largest to date.

ABOUT AMP: The Association for Molecular Pathology (AMP) is an international medical professional association dedicated to the advancement, practice, and science of clinical molecular laboratory medicine and translational research based on the applications of molecular biology, genetics, and genomics. For more information, please visit http://www.amp.org.

CONTACT: Mary Steele Williams mwilliams@amp.org (301) 634-7921

###

See more here:
AMP Receives 40% Increase in Abstract Submissions

GenMark Diagnostics Appoints Stephen T. Worland, Ph.D. to Board of Directors

CARLSBAD, Calif.--(BUSINESS WIRE)--

GenMark Diagnostics, Inc. (NASDAQ: GNMK), a provider of automated, multiplex molecular diagnostic testing systems, announced today that Dr. Stephen T. Worland has been appointed to GenMark's Board of Directors.

Stephen Worland has extensive experience in global technology, infectious disease and healthcare businesses and is currently President and Chief Executive Officer and a director of eFFECTOR Therapeutics, Inc., a start-up stage company focused on new treatments for cancer. Dr. Worland was President and Chief Executive Officer and a director of Anadys Pharmaceuticals, Inc., a biopharmaceutical company which discovered and developed treatments for Hepatitis C and cancer, from August 2007 until the companys acquisition by Roche in November 2011. Dr. Worland joined Anadys in 2001 and served in a number of executive roles prior to being named CEO, including President, Pharmaceuticals, and Chief Scientific Officer. Dr. Worland began his healthcare industry career in 1988 at Agouron Pharmaceuticals, Inc. and remained with the company through its successful commercialization of an HIV protease inhibitor and successive acquisitions by Warner-Lambert and Pfizer. During this period he held a number of positions, including Vice President, Antiviral Research and Director, Molecular Biology and Biochemistry. Dr. Worland was a National Institutes of Health Postdoctoral Fellow in Molecular Biology at Harvard University from 1985 to 1988. He received his B.S. with highest honors in Biological Chemistry from the University of Michigan and his Ph.D. in Chemistry from the University of California, Berkeley.

"We are delighted to have Steve Worland join our Board. In addition to his extensive operational experience in the Pharmaceutical industry, both in small and large companies, Steves deep knowledge of molecular biology, specifically as it relates to infectious disease, cancer and related pharmacogenomics, will be invaluable as GenMark continues to build its own molecular diagnostics franchise in these areas. Steves skill set and experience complement an already strong Board that is focused on building a high value business in the global molecular diagnostics market, commented Christopher Gleeson, GenMark's Chairman.

ABOUT GENMARK

GenMark Diagnostics is a leading provider of automated, multiplex molecular diagnostic testing systems that detect and measure DNA and RNA targets to diagnose disease and optimize patient treatment. Utilizing GenMark's proprietary eSensor detection technology, GenMark's eSensor XT-8 system is designed to support a broad range of molecular diagnostic tests with a compact, easy-to-use workstation and self-contained, disposable test cartridges. GenMark currently markets three tests that are FDA cleared for IVD use: Cystic Fibrosis Genotyping Test, Warfarin Sensitivity Test, and Thrombophilia Risk Test. A Respiratory Viral Panel (RVP) has been submitted to the FDA for 510(k) clearance. A number of other tests, including HCV Genotyping and 2C19, versions of which are available for research use only, are in development for IVD use. For more information, visit http://www.genmarkdx.com.

SAFE HARBOR STATEMENT

This press release includes forward-looking statements regarding events, trends and business prospects, which may affect our future operating results and financial position. Such statements, including, but not limited to, those regarding continued growth in sales of our diagnostic tests, the expansion of our diagnostic test menu, the development and functionality of our products and the continued development of our technology, are all subject to risks and uncertainties that could cause our actual performance, operating results and financial position to differ materially. Some of these risks and uncertainties include, but are not limited to, risks related to our history of operating losses, our ability to successfully commercialize our products, the need for further financing and our ability to access the necessary additional capital for our business, inherent risk and uncertainty in the protection intellectual property rights, ability to maintain gross margins, regulatory uncertainties regarding approval or clearance for our products, as well as other risks and uncertainties described under the "Risk Factors" in our public filings with the Securities and Exchange Commission. We assume no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made.

Link:
GenMark Diagnostics Appoints Stephen T. Worland, Ph.D. to Board of Directors

Research and Markets: European Molecular Diagnostics Markets

DUBLIN--(BUSINESS WIRE)--

Dublin - Research and Markets (http://www.researchandmarkets.com/research/7m2ls7/european_molecular) has announced the addition of Frost & Sullivan's new report "European Molecular Diagnostics Markets" to their offering.

This Frost & Sullivan research service titled European Molecular Diagnostics Markets provides a comprehensive analysis of key challenges, drivers, and restraints as well as recent venue forecasts. It also examines major trends and initiatives in the molecular diagnostics market. The research covers oncology, genetic diseases, infectious diseases and pharmacogenomics segments.

Market Overview

Automation to Play Important Role in Expansion of Molecular Diagnostics Markets

The potential for enhanced clinical efficiency and reduced costs is fuelling the interest of healthcare stakeholders in personalised and preventive medicine. Molecular diagnostics is a vital tool to support this trend. Available molecular diagnostics technologies can detect diseases at very early stages and help monitor the efficacy of therapies being used in disease treatment. Technology advances, paralleled by the decreasing cost of automated systems, will boost market prospects, notes the analyst of this research. Automation, in particular, will play an increasingly important role in market expansion.

Many molecular diagnostic methods were historically based on steps of manual pipetting. Automated devices are nowadays replacing them and offer numerous advantages. These include faster turn-around time (TAT), manipulation of smaller volumes of liquids as well as more accurate and quantifiable results, compared to manual methods. Automation is currently of interest mostly among large diagnostic laboratories, but it is expected that, over time, automated systems will also be available at smaller laboratories, remarks the analyst. In small and medium-sized laboratories, if automation is implemented at all, it is likely to be based on single function automated devices rather than fully automated, comprehensive systems. However, automation of molecular diagnostics is still considered to be insufficient. This is especially the case in sample preparation and nucleic acid extraction, where the majority of work is performed manually. This leads to prolonged TAT, which is a challenge, especially when immediate results are required.

Market Sectors

Expert Frost & Sullivan analysts thoroughly examine the following market segments in this research:

- Oncology

Go here to see the original:
Research and Markets: European Molecular Diagnostics Markets

Research and Markets: Pharmacogenetics and Individualized Therapy

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/xp9wx4/pharmacogenetics_a) has announced the addition of John Wiley and Sons Ltd's new book "Pharmacogenetics and Individualized Therapy" to their offering.

The One-Stop Reference To Pharmacogenetics And Its Impact On Pharmaceuticals, Therapeutics, And Clinical Practices

Pharmacogenetics and Individualized Therapy offers thorough coverage of the study of the genetic determinants of drug response at the single gene leveland its impact on pharmaceuticals, therapeutics, and clinical practice. Providing an overview of the molecular basis of pharmacogenetics, the book helps readers understand the implications of genetic variability on pharmacokinetics and pharmacodynamics, as well as other aspects such as adverse drug reactions. Providing coverage of specific disease areas, including cardiovascular concerns, cancer and asthma/COPD, transplantation, and pain medication, the book also looks at the clinical practices, along with the psychiatric and ethical issues that have come to dominate conversation about pharmacogenetics.

The technological applications of pharmacogenetics, including genotyping, drug disposition (metabolism and enzymes), and the impact of this research on the pharmaceutical industry and regulatory matters are all addressed in chapters by internationally recognized leaders from both academia and industry.

Including chapters on specific therapeutic areas and clinical aspects, Pharmacogenetics and Individualized Therapy helps readers, whether they're students or researchers, to understand the implications of genetic variability on pharmacokinetics and pharmacodynamics.

Authors

ANKE-HILSE MAITLAND-van der ZEE, PhD, is Associate Professor of Pharmacogenetics

Pharmacogenomics at Utrecht University, the Netherlands.

ANN K. DALY, PhD, is Professor of Pharmacogenetics at Newcastle University, UK.

Read the rest here:
Research and Markets: Pharmacogenetics and Individualized Therapy

Life Technologies Showcases Leading Technologies for Companion Diagnostic Development, Cancer Research at the ASCO …

CARLSBAD, Calif., June 1, 2012 /PRNewswire/ --Life Technologies Corporation (LIFE) will exhibit platforms for companion diagnostic development and products ideal for basic, translational and clinical cancer research during the American Society for Clinical Oncology (ASCO) Annual Meeting 2012, taking place June 1 June 5, in Chicago, Illinois. In addition, several of the company's customers will present clinical research findings obtained with Life's sequencing technologies.

"Life Technologies offers platforms across the spectrum of genomics and proteomics that can be utilized in companion diagnostic development," said Ronnie Andrews, president of medical sciences at Life Technologies. "We share with our pharma partners a dedication to the movement toward personalized treatments based on the specific defects driving cancer in each individual patient."

In October 2011, Life announced a partnership with GlaxoSmithKline to develop a companion molecular test for a GSK candidate cancer immunotherapy.

Presentations:

AmpliSeq panels accurately identify more than 700 mutations in patient samples Marilyn Li, Ph.D., professor of molecular and human genetics and director of the Cancer Genetics Lab at Baylor College of Medicine, will present a poster demonstrating use of the Life Technologies Ion AmpliSeq cancer panels to sequence 12 archived tumor research samples including FFPE, bone marrow and cell line samples. The authors report that the panel accurately identified all known mutations previously detected using Pyrosequencing or Sanger sequencing and was sensitive enough to detect mutations at frequencies as low as 5% with 99% confidence. The poster will be presented June 4, Monday afternoon from 1:15 to 5:15.

AmpliSeq panels validated in CLIA lab with rapid turn-around for tumor sample sequencing Christopher Corless, M.D., Ph.D., chief medical officer of the Knight Diagnostic Laboratories at Oregon Health & Science University's Knight Cancer Institute, will present results using the Ion Torrent (Life Technologies) AmpliSeq Cancer Panel in a CLIA-licensed/CAP-certified setting. Forty-five FFPE tumor samples were sequenced, and the results matched those obtained via previous mass spec-based genotyping and revealed an additional 27 new mutations. Preliminary data from a custom AmpliSeq GI Stromal Tumor (GIST) panel will also be shown. The poster will be presented June 4, Monday afternoon from 1:15 to 5:15.

Featured Products:

Life Technologies offers cancer researchers the ability to detect mutations in cancer-associated genes using both PCR and sequencing platforms.

Ion Personal Genome Machine (Ion PGM) and Ion Proton Between the benchtop Ion PGMSequencer and the benchtop Ion ProtonSequencer, the Ion Torrent technology can cover any application. The Ion PGMSequencer is ideal for sequencing genes, small genomes, panels of genes, or performing gene expression profiling, and its speed, simplicity and scalability also make it an ideal platform to extend into diagnostics.

The Ion ProtonSequencer is ideal for sequencing both exomes regions in the DNA that code for protein and human genomes. The Ion ProtonI Chip, ideal for sequencing exomes, will be available mid-2012. The Ion ProtonII Chip, ideal for sequencing whole human genomes, will be available six months later. In addition, the Ion ProtonOneTouchsystem automates template prep and a stand-alone Ion ProtonTorrent Server performs the primary and secondary data analysis.

See the original post:
Life Technologies Showcases Leading Technologies for Companion Diagnostic Development, Cancer Research at the ASCO ...

Leading Anti-Cancer Drugs and Associated Market 2012-2022

NEW YORK, June 4, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Leading Anti-Cancer Drugs and Associated Market 2012-2022

http://www.reportlinker.com/p0819459/Leading-Anti-Cancer-Drugs-and-Associated-Market-2012-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

Report Details

Cancer treatments - discover which products have greatest potential

Where are cancer-treating drugs heading? Visiongain's report shows you potential revenues to 2022, with data, forecasts and discussions.

This study investigates leading drugs to treat human cancers. It lets you assess potential sales trends at world market, therapeutic submarket, product and national level to 2022.

How will 25 leading products - including Avastin, Rituxan, Herceptin and Glivec/Gleevec - perform from 2012? See potential revenues and other information. The study also assesses eight recently approved drugs.

Our investigation gives you business research and analysis with sales forecasts. You also see forecasting of five submarkets to 2022, finding potential revenues:

Traditional antineoplastic agents

Read more here:
Leading Anti-Cancer Drugs and Associated Market 2012-2022

Outsourcing in Drug Discovery: The Contract Research Organization (CRO) Market, 5th Edition

NEW YORK, June 6, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Outsourcing in Drug Discovery: The Contract Research Organization (CRO) Market, 5th Edition

http://www.reportlinker.com/p0203691/Outsourcing-in-Drug-Discovery-The-Contract-Research-Organization-CRO-Market-5th-Edition.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Discovery_and_Development

The drug discovery process is long, arduous and costly, which has driven outsourcing in this field. The first phase is discovery of a lead compound, a molecule that affects biological function by binding to a target protein or nucleic acid in a way that is useful for treatment of disease. The process by which molecules are identified for their therapeutic value involves synthesis and analysis of many derivatives of the original leads. There are several steps in the drug discovery process including hit confirmation, lead generation, lead optimization, and other studies. Drug discovery is a high-cost, risky business because only a fraction of the therapeutic targets selected for study will actually yield products that achieve regulatory approval by the Food & Drug Administration (FDA).

Since the last edition of Kalorama's Report on the outsourcing of discovery of novel compounds in the pharmaceutical industry, the industry has seen dramatic change. Pharmaceutical companies facing cutbacks in R&D budgets and new demands for novel products need to outsource aspects of their operations. Core functions once kept in-house such as the discovery of potential new drugs are now commonly outsourced. Kalorama Information's Outsourcing in Drug Discovery captures this trend, offering unparalleled coverage of the drug discovery outsourcing market. It presents viewpoints from both customers and suppliers. Segments, size, and growth of the market are presented. The trend toward the increased use of offshore suppliers in China, India, Russia and Eastern Europe is covered in detail. The report also provides profiles of 23 suppliers, representative of those active in this market.

Segments covered in this report with market size estimates include:

In addition to market data and forecasts, the report covers issues such as:

This report provides an in depth look into the trends that have shaped the drug discovery outsourcing market today, and details the current and future global market.

The information for this report was gathered using both primary and secondary research including comprehensive research of secondary sources such as company literature, databases, investment reports, science, medical and business journals. Telephone interviews and email correspondence were the primary method of gathering information. For the purpose of this study Kalorama Information conducted interviews with key industry officials, consultants, and government personnel. These sources were the primary basis in gathering information specifically relating to revenue and market share data presented in this report. Specific interviews with pharmaceutical, biotechnology and contract research organizations included marketing directors, division managers, and product representatives.

CHAPTER ONE: EXECUTIVE SUMMARY

View original post here:
Outsourcing in Drug Discovery: The Contract Research Organization (CRO) Market, 5th Edition

Armuchee junior to study human genetics at Duke University this summer

by Floyd County Schools reports Rn T.Com

With small class sizes, the highly-selective courses in the Duke program are very competitive with limited availability. Just to be eligibility for enrollment is an honor and indicates the student has exhibited outstanding intellectual ability and dedication to academics. Duke TIP provides participants with an exciting, stimulating and challenging opportunity to augment their interests and capabilities. Through a variety of experiential activities, lab work, discussions, fieldwork, collaboration, presentations, and the use of advanced technology and lab equipment, participants in the genetics program will delve into cutting-edge human genetic research. Topics included in the program are: human gene expression, pharmacogenomics, and epigenetic control of DNA, SNP genotyping, gene sequencing, forensic biology, and medical genetics. Hosmer's experience will culminate with the creation of an individual laboratory project that she will present to Duke faculty and her institute peers.

At Armuchee High School, Hosmer is involved with the National Honors Society and Academic Decathlon and she has maintained a 4.0 GPA. Hosmer also volunteers in the community at Mount Berry Animal Hospital and the Rome Action Ministries Food Pantry. She plans to pursue undergraduate degrees in Biology and Veterinarian Sciences at Berry College or at the University of Georgia before deciding upon a school of medicine.

Click here to read additional press releases on RN-T.com.

See original here:
Armuchee junior to study human genetics at Duke University this summer

AssureRx Health Raises $12.5 Million Series C Financing

MASON, Ohio, May 30, 2012 /PRNewswire/ --AssureRx Health, Inc. today announced the closing of a $12.5 million Series C financing. The personalized medicine company, which provides clinically-relevant information to help physicians select the right drug for individual neuropsychiatric patients, will use the funds to increase commercial activities for its two flagship pharmacogenomic products, GeneSightRx Psychotropic and GeneSightRx ADHD, as well as next generation product development activities.

The financing was led by Four Rivers Group and existing investors Claremont Creek Ventures and Sequoia Capital. The financing also included participation of existing investors Cincinnati Children's Hospital Medical Center, Mayo Clinic, CincyTech, Allos Ventures, as well as new investors jVen Capital and Alafi Capital. New investors Four Rivers, jVen Capital, and Alafi Capital bring to AssureRx Health further expertise and partnering connections to help AssureRx Health continue building its leadership position in psychiatric pharmacogenomics.

"Our goal is to build the leading clinical informatics company providing pharmacogenomic and other treatment decision support products to help physicians individualize the treatment of patients with neuropsychiatric and other disorders," said James S. Burns, president and CEO of AssureRx Health. "Proceeds from the Series C financing will be used to expand sales coverage, sponsor multiple clinical studies, and develop new products to help accelerate our leadership position in psychiatric personalized medicine."

Warren Hogarth, partner at Sequoia Capital, said, "AssureRx products have the potential to change the way physicians select the appropriate medications for each of their patients. AssureRx is at the cutting edge of providing treatment decision support products for a very large global psychiatric market. We believe that AssureRx Health is building a world class company."

John Steuart, managing director of Claremont Creek Ventures said, "AssureRx has enormous potential to lead the transformation of neuropsychiatric care toward personalized patient treatment. GeneSightRx Psychotropic, GeneSightRx ADHD and future pharmacogenomic products hold the promise for faster, better patient outcomes and less costly care. We believe that AssureRx products have the potential for significant adoption by the psychiatric community, leading ultimately to incorporating pharmacogenomics into routine psychiatric practice guidelines."

From a simple cheek swab, the GeneSightRx technology measures and analyzes clinically important genetic variants that determine how a patient's unique genetic make-up affects his or her ability to tolerate or effectively respond to psychotropic medications. Patient-specific genetic information obtained through GeneSightRx can assist physicians in the process of selecting appropriate antidepressant and antipsychotic medications for individual patients.

About Claremont Creek Ventures Claremont Creek Ventures (CCV) is a seed and early stage venture firm. CCV invests in digital healthcare, energy technology, payments/commerce, and online businesses. Utilizing the firm's proprietary life-cycle venturing program, Claremont Creek Ventures also partners with entrepreneurs and institutions, including UC Berkeley, Lawrence Livermore Labs, Stanford University and UC Davis. Claremont Creek has more than $300 million in capital under management in two funds. CCV's digital healthcare investments in addition to AssureRx Health include Genalyte, GeneWeave, GigaGen, Fluxion Biosciences, Natera, Tibion and Zipline Medical. For more information, visit http://www.claremontcreek.com.

More:
AssureRx Health Raises $12.5 Million Series C Financing

ACM Global Central Laboratory Appoints Mark Engelhart as Chief Commercial Officer

ROCHESTER, N.Y.--(BUSINESS WIRE)--

ACM Global Central Lab, the central laboratory that continually defines the customer-service standard with its flexible approach, is pleased to announce that Mark Engelhart has joined the executive management team as chief commercial officer. Engelhart will be responsible for leading ACM Globals business development, proposals and contracts, marketing and sales activities worldwide.

Prior to joining ACM Global, Engelhart was chief commercial officer at Cryoport, Inc. a provider of leading-edge cold chain logistics services. His experience also includes serving in varying sales and marketing management and operations roles at leading pharmaceutical companies, including Bayer and Abbot Laboratories. Engelhart has also held the role of vice president of global sales and marketing at Covance Laboratory, Quest Diagnostics Clinical Trials division and Esoterix Clinical Trials Services.

We are extremely pleased to have Mark join ACM Global, said Angela J. Panzarella, president of ACM Global Central Lab. Mark is a highly accomplished senior executive with deep experience in sales, marketing, strategy, and global commercial operations for central laboratory services and clinical trials support services, and will be a valuable addition to our executive team.

ACM Global will be on hand to discuss the latest trends in clinical research lab testing at PCMG Annual Conference, June 13-15 at the Pine Cliffs Hotel in Portugal and at the 48th Annual DIA Meeting, June 24-28 in Philadelphia.

About ACM Global Central Lab

ACM Global Central Lab offers a flexible approach and a focus on precision to keep clinical research studies on schedule. ACM Globals services extend to more than 60 countries with all tests conducted and managed from central lab facilities with seamless data management providing a single database. The organization performs 14 million tests each year, featuring more than 1,500 individual tests spanning all medical disciplines, including pathology, microbiology, flow cytometry and pharmacogenomics. Combining comprehensive safety, efficacy and pathology testing from a single lab ensures clients receive consistent, analyzable test results with faster and cleaner reporting.

For more information, visit http://www.acmgloballab.com, our Central Labs in Focus blog or call +1 866 405 0400.

See the rest here:
ACM Global Central Laboratory Appoints Mark Engelhart as Chief Commercial Officer

The Ventyx Wesley Research Institute Tissue Bank Joins the BioServe Network

BELTSVILLE, MD--(Marketwire -05/16/12)- BioServe today announced that the Ventyx Wesley Research Institute Tissue Bank, the largest state-of-the-art bio-repository of human tissue and blood in Queensland, Australia, has joined BioServe's network of affiliated bio-repositories. As part of the BioServe Network, the Ventyx Wesley Research Institute Tissue Bank will make available its high volume of oncology tissue and blood samples to industry and academic researchers worldwide. The collaborative partnership between BioServe and the Wesley Research Institute was facilitated by Bio-Link Australia Pty. Ltd., a life sciences commercialisation company.

The Ventyx Wesley Research Institute Tissue Bank joins the growing BioServe Network that includes Fox Chase Cancer Center, University of Massachusetts Medical School, the Windber Research Institute, and Maine Medical Center. The Network, along with BioServe's Global BioRepository, creates the largest commercial-ready specimen repository in the world with over 2 million samples in most major diseases. Such specimens hold the data driving genetic and biomarker discovery and validation for effective patient stratification, drug discovery and development of new diagnostics.

The Ventyx Wesley Research Institute Tissue Bank was founded in 2007 and is a purpose-built research facility established to provide a diverse collection of ethically obtained tissue specimens for biomedical research. The Tissue Bank operates at the Wesley Research Institute, which is located on the Wesley Hospital campus in Auchenflower, Brisbane. It collects and stores tissue samples, blood and related clinical data from consenting patients at The Wesley Hospital and makes these specimens and clinical data available to ethically approved medical researchers. The Tissue Bank adheres to the international standards set down in Good Clinical Practice and Good Laboratory Practice guidelines.

"We are pleased that the Ventyx Wesley Research Institute Tissue Bank will make its high quality tissue samples available through the BioServe Network. By tapping this unique and comprehensive sample resource, researchers can quickly obtain most any type of human biological sample in most any disease," said Rama Modali, President of BioServe.

"Becoming part of the BioServe Network will enable us to reach a greater proportion of the scientific research community, putting our samples into the hands of researchers developing new therapies and diagnostics," said Dr. Greg Hafner, Chief Operations Officer of the Wesley Research Institute.

About BioServe BioServe provides a comprehensive 'biomaterial to validated data' genomics services platform, helping researchers gain the pre-clinical data for breakthroughs in drug discovery, molecular diagnostics and pharmacogenomics. Utilizing BioServe's genomics services platform, researchers can identify genetic markers, validate drug targets and correlate clinical data with molecular data to accelerate the development of new and safer drugs. BioServe's services extend from nucleic acids processing, DNA synthesis, high throughput genotyping, genome wide-scans and gene expression analyses to ready-made large epidemiologically sound case-control studies of inflammatory disorders, endocrine disorders, cardiovascular disease, diabetes, hypertension, obesity and many cancers. BioServe's Global BioRepository provides researchers with a library of 600,000 human DNA, tissue and serum samples linked to detailed clinical and demographic data from 120,000 consented and anonymized patients from four continents.

For more information please visit http://www.bioserve.com or call 301-470-3362.

About Wesley Research InstituteThe Wesley Research Institute is an independent, not-for-profit medical research organisation that conducts research focusing on improving patient care and quality of life. Its clinical and applied research aims to discover, test and refine new techniques for better diagnosis and treatment of illness and disease that work towards its motto of 'making a difference today.' Wesley Research Institute provides a range of scientific services across three main areas -- Investigative Research, Clinical Trials and Tissue Banking.

For more information please visit http://www.wesleyresearch.org.au or email enquiries@wesleyresearch.com.au.

About Bio-Link AustraliaBio-Link Australia Pty. Ltd., with offices in Melbourne and Sydney, is a life sciences commercialisation company offering professional business development services to facilitate commercial partnerships in the biopharmaceutical and diagnostic industries. Bio-Link's clients include leading biotechnology companies and medical research institutes located in Australia and around the world. For more information please visit http://www.bio-link.com.

See the rest here:
The Ventyx Wesley Research Institute Tissue Bank Joins the BioServe Network

Transgenomic Reports First Quarter 2012 Financial Results

OMAHA, Neb.--(BUSINESS WIRE)--

Transgenomic, Inc. (OTCBB: TBIO.OB - News) today reported financial results for the three months ended, March 31, 2012, and provided a business update.

We made progress in the first quarter validating and advancing several of our new high-value products, including the NuclearMitome Test, ICE COLD-PCR in circulating tumor cells and PGxPredict:CLOPIDOGREL response panel, said Craig Tuttle, President and Chief Executive Officer. Our investment in these groundbreaking new products and technologies will fuel growth over the long term and keep Transgenomic at the forefront of the pharmacogenomics and molecular diagnostics industry. Most notably, we continue to build momentum in building awareness around our proprietary, two gene clopidogrel response panel, a test which represents a potential multi-billion dollar market opportunity.

Mr. Tuttle added, Supporting our strategic initiatives was a $22 million private placement financing executed in the first quarter. Together with our focus on the successful development of new products and technologies, and the expansion of our commercial products into new markets, we believe Transgenomic has the strategy, balance sheet strength and operational infrastructure to achieve significant value creation.

Recent Corporate and Business Events

First Quarter Financial Results

Net sales for the first quarter of 2012 were $7.2 million compared with $7.5 million for the same period in 2011. Gross profit was $3.1 million or 43 percent of net sales, compared with gross profit of $4.2 million or 56 percent of net sales for the same period in 2011.

The decrease in revenue is primarily due to a software failure that temporarily resulted in reduced sample processing capacity at the Companys New Haven, Connecticut laboratory testing facility. The Company believes that full sample processing capacity has been restored and expects to complete the sample backlog caused by the LIMS failure by June 2012 in addition to processing the entire volume of samples received during the second quarter. This revenue decrease was partially offset by an increase in instrument deliveries during the quarter.

Operating expenses were $5.5 million during the first quarter of 2012, compared with $4.9 million in the prior year. The largest increase is the recognition of stock options granted in 2011.

The net loss for the first quarter of 2012 was $2.7 million or $0.05 per share compared with a net loss of $2.8 million or $0.06 per share for the first quarter of 2011.

Read more from the original source:
Transgenomic Reports First Quarter 2012 Financial Results

Aviir Laboratories Announce National Agreement with Three Rivers Provider Network

IRVINE, Calif., May 7, 2012 /PRNewswire/ -- Aviir Diagnostic Laboratory has entered into a contractual agreement for ancillary diagnostics laboratory testing as a participating provider with TRPN and its 10 million lives network.

Three Rivers Provider Network (TRPN) was founded in 1996 as a company that was contracted to provide services for several major clients. At that time, its clients needed to access a network that would grant PPO type discounts without incurring balance billing risks for their members. Over time, given superior results and the high levels of satisfaction of service that were achieved, TRPN was prompted by other companies that focused on group health and workers compensation to perform similar type services for them.

Since that time, TRPN has evolved into the largest and fastest growing proprietary PPO network in the United States. The TRPN network is now comprised of more than 600,000 total providers, including more than 5,000 hospitals and 70,000 ancillary facilities. Through its clients, approximately 10 million lives now have access to the TRPN PPO network.

Aviir was founded in 2005 by cardiologists and scientists from the Stanford University School of Medicine to focus on discovery, development and commercialization of innovative diagnostic tests.The biotechnology company specializes in developing proprietary diagnostic teststhat will assist in identifying patientswho are truly at high risk for the development of a cardiac event.Aviir's proprietary MiRisk and TruRisk assessments objectively identify, by a simple blood draw, individuals who are at a high risk of a cardiac event over the next five years.Aviir's CLIA laboratory (Irvine, CA) complements these novel tests with a wide range of additional tests for risk assessment and therapeutic monitoring of cardiovascular disease and related metabolic disorders including pharmacogenomics and genetic tests. http://www.aviir.com

"There is currently a significant yet unmet clinical need in the medical community for more effective ways to identify individuals at high risk of a heart attack who are missed by current evaluation methods. Providing an accurate assessment of the patient's overall heart health is the first step in prevention of cardiovascular disease," stated Douglas Harrington, M.D., Chief Executive Officer of Aviir.

"At Aviir, our ultimate goal is to help physicians identify those patients who are at serious risk of experiencing a heart attack but are completely unaware of their precarious condition. Armed with better information, physicians will be able to customize individualized treatment plans with the goal of improving patient therapeutic compliance, reducing their risk of heart attacks, and decreasing the overall cost of care," Dr. Harrington added.

Learn more at http://www.aviir.com Learn more at http://www.trpnppo.com

For more information: Dina Scaglione Marketing, Communications Manager Dina.Scaglione@aviir.com

View original post here:
Aviir Laboratories Announce National Agreement with Three Rivers Provider Network

A Conversation with CeGaT's Saskia Biskup

Pacific Biosciences said this week that Karen Bray has joined the company as VP of North American Sales. Bray previously was a sequencing sales leader at Life Technologies selling Ion Torrent and SOLiD systems in the Southeast and Mid-Atlantic regions, and before that she held sales posts at Beckman Coulter, Fisher Scientific, and Whatman.

Real Time Genomics has appointed Steve Lombardi to be company president and CEO, the genomic analysis software company said this week. Lombardi was president and then CEO of Helicos Biosciences between 2006 and 2010, and he was a senior executive involved in corporate development and business management at Affymetrix between 2002 and 2006. He also held several sales and management positions at Applied Biosystems in product, sales, and business management from 1986 to 2002.

Fluidigm has tapped Dan Clutter as North American sales director for its eastern sales region. He will be responsible for sales growth in the eastern US and Canada and will be a member of Fluidigm's North American commercial leadership team, according to a spokesperson. Clutter joins Fluidigm from Gentel Biosciences, where he had served as vice president of commercial development since 2009. Before that, he was vice president of sales at NimbleGen Systems, now Roche NimbleGen.

See original here:
A Conversation with CeGaT's Saskia Biskup